Metabolomic Biomarkers of Pulmonary Fibrosis in COVID-19 Patients One Year After Hospital Discharge
Coronavirus disease 2019 (COVID-19) global pandemic has affected more than 600 million people up to date. The symptomatology and severity of COVID-19 are very broad, and there are still concerns about the long-term sequelae that it can have on discharged patients. The development of pulmonary fibrot...
| Autores: | , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2025 |
| País: | España |
| Institución: | Centro de Investigación Principe Felipe (CIPF) |
| Repositorio: | r-CIPF. Repositorio Institucional Producción Científica del Centro de Investigación Principe Felipe (CIPF) |
| OAI Identifier: | oai:cipf.fundanetsuite.com:p4549 |
| Acceso en línea: | https://cipf.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4549 |
| Access Level: | acceso abierto |
| Palabra clave: | H-1-NMR spectroscopy biomarkers COVID-19 metabolomics pulmonary fibrosis |
| Sumario: | Coronavirus disease 2019 (COVID-19) global pandemic has affected more than 600 million people up to date. The symptomatology and severity of COVID-19 are very broad, and there are still concerns about the long-term sequelae that it can have on discharged patients. The development of pulmonary fibrotic sequelae after this infection is especially worrying. Our aim was to determine if there was a metabolomic signature that could predict the development of pulmonary fibrotic sequelae. It is a multicenter prospective observation subcohort based on the COVID-FIBROTIC study. A metabolomic analysis was performed by nuclear magnetic resonance (NMR) on serum samples from patients admitted with bilateral COVID-19 pneumonia collected 2 months after hospital discharge. One year after admission, clinical, functional and radiological data were collected from these same patients. Finally, 109 patients (mean age 57.68 [DS14.03], 65.13% male) were available. Fibrotic sequelae 1 year after COVID-19 disease were found in 33% of them. Based on the NMR analysis of the serum samples, it was possible to distinguish with 80.82% of sensitivity, 72.22% of specificity and 0.83 of an area under the curve (AUC) value which patients would have radiological signs of pulmonary fibrotic pattern 1 year after sample collection. According to the metabolites participating in the discriminative model and the univariate statistics, glucose, valine, and fatty acids (& boxH;CH-CH2-CH & boxH;) were suggested as potential biomarkers of the development of pulmonary fibrotic sequelae after COVID-19. |
|---|